For: | Kim JJ, Park YJ, Moon KY, Park JH, Jeong YK, Kim EY. Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock. World J Gastrointest Surg 2019; 11(12): 422-432 [PMID: 31879534 DOI: 10.4240/wjgs.v11.i12.422] |
---|---|
URL: | https://www.wjgnet.com/1948-9366/full/v11/i12/422.htm |
Number | Citing Articles |
1 |
Sergio Garcia-Ramos, Estrela Caamaño, Patrocinio Rodríguez Benítez, Pilar Benito, Alberto Calvo, Silvia Ramos, Mercedes Power, Ignacio Garutti, Patricia Piñeiro. Mortality Risk Prediction in Abdominal Septic Shock Treated with Polymyxin-B Hemoperfusion: A Retrospective Cohort Study. Journal of Personalized Medicine 2023; 13(7): 1023 doi: 10.3390/jpm13071023
|
2 |
Salvatore Lucio Cutuli, Silvia De Rosa, Ricard Ferrer, Juan Carlos Ruiz‐Rodriguez, Francesco Forfori, Claudio Ronco, Massimo Antonelli. Endotoxin activity trend and multi‐organ dysfunction in critically ill patients with septic shock, who received Polymyxin‐B hemadsorption: A multicenter, prospective, observational study. Artificial Organs 2023; 47(8): 1361 doi: 10.1111/aor.14534
|
3 |
Claudio Ronco, Thiago Reis. Continuous renal replacement therapy and extended indications. Seminars in Dialysis 2021; 34(6): 550 doi: 10.1111/sdi.12963
|
4 |
Won Young Lee, Hee Ju Kim, Eun Young Kim. Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-03055-8
|
5 |
Hye Sung Kim, Yoon Ji Chung, Gyeo Ra Lee, Eun Young Kim. The clinical efficacy and suitable implementation of two extracorporeal blood purification therapies: AN69-oXiris versus PMX-HP. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1344893
|